Importance of Prevention Strategies to Lower Healthcare Cost

January 10, 2024

To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.

Chronic diseases contribute significantly to health and economic costs in the United States. The leading chronic diseases, heart disease, stroke, cancer, and diabetes, account for $4.1 trillion in annual healthcare expenditures (1). Approximately one third of the deaths in the U.S. are caused by heart disease or stroke, which adds approximately $216 billion annually in healthcare system costs, and $147 billion (2) in job productivity losses. In 2017, diabetes diagnoses cost an estimated $327 billion (2). In addition, almost 600,000 people die from cancer each year, which is expected to add $240 billion to healthcare system expenses by 2030. To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention. Prevention is the effort to improve health, such as screening, health education, adherence to therapy, and adopting an overall healthy lifestyle. There are three different types of prevention (8):

Prevention can be accomplished individually, however, managed care organizations, health plans and employers can contribute by establishing strategies to help the insured adhere to prevention and treatment regimens to manage their health conditions. For the insured, this may represent a better quality of life, better health, and improved work performance.


One strategy that may help the insured optimize their treatment and help lower healthcare costs is a Diabetes Prevention Program (DPP).  These programs have proven to reduce risk of diabetes, especially in people with pre-diabetes, via management of lifestyle changes (4). A DPP is a lifestyle management program proven to reduce the risk of diabetes among people with pre-diabetes through improved eating patterns, physical activity, and weight loss. For example, DPP has shown to cost effectively reduce diabetes by 58% and demonstrate healthcare savings of more than $3,000 in 3 years (4). DPP participants have lost an average weight of 4.3%, and program participation is associated with preventing other health conditions such as obesity, hypertension, and dyslipidemia. Another tool in the arsenal of prevention includes wellness programs. A wellness program is a social/lifestyle program intended to improve and promote health and fitness, usually offered through the workplace or through insurance plans directly to their enrollees (10). This has many benefits – for example, more productivity, increased employee morale, reduced absenteeism, and improved recruitment and retention of employees.


For primary prevention strategies, MC-Rx promotes access and appropriate utilization of immunizations, such as influenza, Covid-19, and pneumonia vaccines. Every year the U.S. spends approximately $27 billion treating diseases that could have been prevented by vaccinations (3). For every $1 spent on childhood vaccinations, there is a cost avoidance of $10.90 (3). According to the CDC, by 2021, 2.9 million medical visits, 65,000 hospitalizations, and 3,900 deaths were prevented by influenza vaccination6. Most recently, Covid-19 vaccines have prevented 18.5 million hospitalizations, and 3.2 million deaths in the United States (9). As for secondary prevention, MC-Rx supports screening, early detection, and management of diseases via educational platforms and health fairs. In addition, MC-Rx provides educational material aimed at patients, providers, health plans, employers, and other insurers to promote health literacy and commitment to a healthy lifestyle. You may visit the company webpage and view our comprehensive educational program including videos and blogs on the latest health topics (https://www.mc-rx.com/).


Finally, for tertiary prevention, MC-Rx ensures appropriate and timely access to important cost-effective, first-line, preventative medications such as statins, to prevent kidney disease in patients with diabetes. We also promote the integration of disease management programs into the pharmacy benefit. These programs exist for a variety of health conditions, including diabetes, hypertension, and obesity. To increase access and convenience, disease management programs can be available through digital platforms. For example, digital therapeutics are innovative applications aimed to treat or alleviate a disease, disorder, condition, or injury, by generating and delivering a medical intervention. It may benefit payers by reducing the overall cost of care by enhancing and optimizing current medical treatments, improving provider communication efficiency, and support value and outcome-based care initiatives (5). Data from digital wellness programs have shown a 9.3% reduction in healthcare utilization, 23.5% reduction in hospitalizations, and $5,077 reduction in cost for cardio metabolic conditions like diabetes (5).


At MC-Rx, we are committed to providing innovative care solutions that support patient access to treatment. One example of our commitment to provide access to affordable, cost-effective care was the early onset adoption of our Biosimilar/Biologic Program. Based on MC-Rx drug utilization data, after one year of implementing this program, the annual savings for our client was approximately 25% and beneficiaries experienced approximately 40% lower out-of-pocket costs.


In conclusion, prevention efforts at the primary, secondary, and tertiary levels help reduce development of chronic conditions and prevent complications of existing medical conditions. At MC-Rx, we challenge ourselves to constantly look for strategic innovation, but keep our focus on the basic clinical principles of patient care, service, and individualized attention. The MC-Rx clinical team of experts is composed of pharmacy doctors that partner with clients to develop drug formularies and clinical programs which focus on delivering access to evidence-based, cost-effective care. 


References:

Health and Economic Benefits of Chronic Diseases. (2023). Centers for Disease Control and Prevention. https://www.cdc.gov/chronicdisease/about/costs/index.htm.

Health and Economic Benefits of Chronic Disease Interventions. (2023). Center for Disease Control and Prevention. https://www.cdc.gov/chronicdisease/programs-impact/pop/index.htm

Vaccines Are Cost Saving. (2020). Vaccinate Your Family. https://vaccinateyourfamily.org/why-vaccinate/vaccine-benefits/costs-of-disease-outbreaks/

Cost Savings and Reduced Health Care Utilization Associated with Participation in a Digital Diabetes Prevention Program in an Adult Workforce Population. (2020). Journal of health economics and outcomes research. https://doi.org/10.36469/jheor.2020.14529

Value of DTx. Digital Therapeutic Alliance. https://dtxalliance.org/

Estimated influenza illnesses, medical visits, hospitalizations, and deaths prevented by vaccination in the United States – 2022-2023 influenza season. (2023). Centers for Disease Control and Prevention. https://www.cdc.gov/flu/about/burden-averted/2022-2023.htm

Prevention. Centers for Disease Control and Prevention. https://www.cdc.gov/pictureofamerica/pdfs/picture_of_america_prevention.pdf

Use of updated COVID-19 vaccines 2023–2024 formula for persons aged ≥6 months: Recommendations of the Advisory Committee on Immunization Practices. (2023). Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/72/wr/mm7242e1.htm#:~:text=Introduction,the%20United%20States%20(1)

Wellness Program. Healthcare.gov. https://www.healthcare.gov/glossary/wellness-programs/


A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
September 21, 2023
Drug prices are on the rise—it’s an inescapable reality at this point.
More Posts
Share by: